Insights into the mechanisms of lymph node metastasis

Cancer

Volumn 98, Issue 2, 2003, Pages 413-423

  Nathanson, S David ^a,b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b Education and Research 7087   (United States)

Author keywords

Directional motility; Lymph node metastasis, lymphangiogenesis, lymphatic markers

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CAPILLARY; CARCINOGENESIS; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; LYMPH FLOW; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TISSUE PRESSURE; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038345318     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11464     Document Type: Article

References (106)

1. Foster RS Jr. The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am. 1996;5:79-104.
2. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987;10: 5-9.
3. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R. From Dukes through Jass. Pathological prognostic indicators in rectal cancer. Hum Pathol. 1994;25:498-505.
4. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001;19:3622-3634.
5. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospitals. Ann Surg. 1894;20:497-504.
6. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995; 130:654-658.
7. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
8. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-401.
9. Carr I. Lymphatic metastasis. Cancer Metastasis Rev. 1983; 2:307-317.
10. Van de Velde CJH, Carr I. Lymphatic invasion and metastasis. Experientia. 1977;33:837-884.
11. Weiss L The pathobiology of metastasis within the lymphatic system. Surg Oncol Clin N Am. 1996;5:15-24.
12. Nathanson SD, Haas GP, Mead MJ, Lee M. Spontaneous regional lymph node metastases of three variants of the B16 melanoma: relationship to primary tumor size and pulmonary metastases. J Surg Oncol. 1986;33:41-45.
13. Nathanson SD, Westrick P, Anaya P, Hetzel FW, Jacobsen G. Relationship of spontaneous regional lymph node metastases to dose of local irradiation of primary B16 melanomas. Cancer Res. 1989;49:4412-4416.
14. Nathanson SD, Nelson L, Anaya P, Havstad S, Hetzel FW. Development of lymph node and pulmonary metastases after local irradiation and hyperthermia of footpad melanomas. Clin Exp Metastasis. 1991;9:377-392.
15. Reintgen D, Cruse CW, Wells K. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-767.
16. Alex JC, Krag DN. The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surg Oncol Clin N Am. 1996;5:33-41.
17. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet. 1966;122:791-798.
18. Minsky BD, Mies C, Rich TA, Recht A. Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer, Int J Radiat Oncol Biol Phys. 1989;17: 311-316.
19. Nathanson SD, Avery M, Anaya P, Sarantou T, Hetzel FW. Lymphatic diameters and lymph clearance rates in a murine melanoma model. Arch Surg. 1997;132:311-315.
20. 99mtechnetium-labeled human serum albumin clearance. Ann Surg Oncol. 1997:4: 161-168.
21. Weiss L, Ward, PM. Lymphogenous and hematogenous metastasis of Lewis lung carcinoma in the mouse. Int J Cancer. 1987;40:570-574.
22. Jain RK, Munn LL, Fukumara D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2:266-276.
23. Lymboussaki A, Achen MG, Stacker SA, Alitalo K. Growth factors regulating lymphatic vessels. Curr Top Microbiol Immunol. 2000;251:75-82.
24. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
25. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672-682.
26. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94:819-825.
27. Mattila MM-T, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer. 2002;98:946-951.
28. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995;76:1772-1778.
29. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:461-485.
30. Skinner KA, Eilber FR. Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:121-127.
31. Hermanek P, Guggenmoos-Holzmann I, Gall FP. Prognostic factors in rectal carcinoma: a contribution to the further development of tumor classification. Dis Colon Rectum. 1989;32:593-599.
32. Swartz MA, Berk DA, Jain RK. Transport in lymphatic capillaries. 1. Macroscopic measurements using residence time distribution theory. Am J Physiol. 1996;270:H324-H329.
33. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70:987-1028.
34. Padera PT, Kadambi A, diTomasso E, et al. Lymphatic metastasis in the absence of functional intratumoral lymphatics. Science. 2002;296:1883-1886.
35. Avery M, Nathanson SD, Hetzel FW. Lymph flow from murine footpad tumors before and after sublethal hyperthermia. Radiat Res. 1992;132:50-53.
36. Nathanson SD, Nelson LT. Interstitial fluid pressure in breast cancer, benign breast conditions and breast parenchyma. Ann Surg Oncol. 1994;1:333-338.
37. Nathanson SD, Nelson L. Rates of Flow of 99m technetium-labeled human serum albumin from peripheral injection sites to sentinel lymph nodes. Ann Surg Oncol. 1996;3:329-335.
38. Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med. 1993;178:2077-2088.
39. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566-3570.
40. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394.
41. Eriksson U, Alitalo K. Structure, expression and receptor binding properties of novel vasculoendothelial growth factors. Curr Top Microbiol Immunol. 1999;237:41-57.
42. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1: 219-227.
43. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech. 2001;55:61-69.
44. Banerji S, Ni J, Wang SX, et al. LYVE-1, new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
45. Wigle JT, Oliver C. PROX-1 function is required for the development of the murine lymphatic system. Cell. 1999; 98:769-778.
46. Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech. 2001;55:108-121.
47. Reichert FL. The regeneration of the lymphatics. Arch Surg. 1926;13:871-881.
48. Clark ER, Clark EL. Observation on the new growth of lymphatic vessels as seen in transparent chambers introduced into the rabbit's ear. Am J Anat. 1931;51:43-87.
49. Johnston M, Walker M. Lymphatic endothelial and smooth muscle cells in tissue culture. In Vitro. 1984;20:566-572.
50. Leak LV, Jones M. Lymphangiogenesis in vitro: formation of lymphatic capillary-like channels from confluent monolayers of lymphatic endothelial cells. In Vitro Cell Dev Biol. 1994;30A:512-518.
51. Pullinger BD, Florey HW. Proliferation of lymphatics in inflammation. J Pathol Bacteriol. 1937;45:157-170.
52. Leak LV, Burke JF. Fine structure of the lymphatic capillary and the adjoining connective tissue area. Am J Anat. 1966; 118:785-809.
53. Berens von Rautenfield D, Lubach D, Wenzel-Hora B, Klanke J, Hunneshagen C. New techniques of demonstrating lymph vessels in skin biopsy specimens and intact skin with the scanning electron microscope. Arch Dermatol Res. 1987;279:327-334.
54. Nathanson SD, Zarbo RJ, Wachna DL, Spence CA, Andrzejewski TA, Abrams J. Microvessels that predict axillary lymph node metastases in breast cancer. Arch Surg. 2000; 135:586-594.
55. Chang L, Kaipainen A, Folkman J. Lymphangiogenesis: new mechanisms. Ann N Y Acad Sci. 2002;979:111-119.
56. Witte MH, Way DL, Witte CL, Bernas M. Lymphangiogenesis: mechanisms, significance and clinical implications. EXS. 1997;79:65-112.
57. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech. 2001;55:92-99.
58. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786-1790.
59. Veikkola T, Jussila L, Makinen T, et al. Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20: 1223-1231.
60. Plate KH. From angiogenesis to lymphangiogenesis. Nat Med. 2001;7:151-152.
61. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumors: does it occur? J Pathol. 2001;193:143-146.
62. Enholm B, Karpanen T, Jeltsch M, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001;88:623-629.
63. Skobe M, Hamberg L, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and recruitment of macrophages by vascular endothelial growth factor-C in melanoma. Am J Pathol. 2001;159:893-903.
64. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001;7:462-468.
65. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423-1425.
66. Gershenwald JE, Fidler IJ. Targeting lymphatic metastasis. Science. 2002;296:1811-1812.
67. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, as a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.
68. Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998; 153:103-108.
69. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer. 1999;80:309-313.
70. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2001;407:249-257.
71. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989;81:570-576.
72. Hellman S, Weicheselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
73. Zeidman I, Copland BE, Warren S. Experimental studies on the spread of cancer in the lymphatic system II. Absence of a lymphatic supply in carcinoma. Cancer. 1955;8:123-127.
74. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst. 2002;94:417-421.
75. Liotta LA, Kohn E. Microenvironment of the tumour-host interface. Nature. 2001;11:375-379.
76. Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M. Neuropilin is expressed by endothelial and tumor cells as isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745.
77. St. Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-1202.
78. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83-90.
79. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor homing peptide with a targeting specificity. Nat Med. 2002; 8:751-755.
80. Willis RA. The spread of tumours in the human body. London: Butterworth, 1952.
81. Yancopoulos GD, Davis S, Gale N, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors in blood vessel formation. Nature. 2000;407:242-248.
82. Fidler IJ. Molecular biology of cancer: invasion and metastasis. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997:135-152.
83. Weiss L, Schmid-Schonbein GW. Biomechanical interactions of cancer cells with the microvasculature during metastasis. Cell Biophys. 1989;14:187-215.
84. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191.
85. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34:997-1004.
86. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
87. Bagglioni M. Chemokines and leukocyte traffic. Nature. 1998;392:565-568.
88. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte migration: the multistep paradigm. Cell. 1994;76:301-314.
89. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56.
90. Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis in gastric carcinoma. Cancer Res. 2002;62:2937-2941.
91. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res. 2001;7:93-97.
92. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001; 7:199-205.
93. Folkman J. A mechanism for regulation of lymphangiogenesis independent of angiogenesis. The Lymphatic Continuum; May 3, 2002; Bethesda, MD. Bethesda: National Institutes of Health, 2002.
94. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph nodes. Science. 2002;296:1869-1873.
95. Stoll S, Delon J, Brotz TM, Germain RN. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science. 2002;296:1873-1880.
96. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles and support immunoglobulin production. J Exp Med. 2000;192:1545-1552.
97. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to the regional lymph nodes. J Immunol. 1999;162:2472-2475.
98. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999;189:451-460.
99. Wiley HE, Gonzalez EB, Maki W, Wu M, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93:1638-1643.
100. Qian F, Hanahan D, Weissman IL. L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis. Proc Natl Acad Sci U S A. 2001;98:3976-3981.
101. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
102. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer. PPO Update. 1997;11:1-23.
103. Gunningham SP, Currie MJ, Han C, et al. The short form of the alternatively spliced flt-4 but not its ligand, vascular endothelial growth factor C, is related to lymph node metastasis in human breast cancers. Clin Cancer Res. 2000;6: 4278-4286.
104. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinomas: much more than a new prognostic tool. J Clin Oncol. 1995; 13:765-782.
105. Thor AD, Yandell DW. Molecular pathology of breast carcinoma. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:375-391.
106. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3:420-427.